PharmTech

Accord Healthcare Inc. Recalls Hydrochlorothiazide Tablets USP 12.5 Mg

The company is voluntarily recalling one lot of Hydrochlorothiazide Tablets USP 12.5 Mg because of a labeling mix-up. On Aug. 27, 2018, Accord Healthcare Inc. announced it was voluntarily recalling ...

PRM Pharma Announces Nationwide Availability of HemiClor® (Chlorthalidone) 12.5 mg: The First FDA-Approved Low-Dose Chlorthalidone Tablet Aligned With Hypertension Guidelines

PRM Pharma, LLC announces the nationwide availability of HemiClor® (chlorthalidone) 12.5 mg tablets, the first and only FDA-approved 12.5 mg formulation of chlorthalidone for the treatment of hyperten ...
Medscape

Lupin Recalls Irbesartan and Hydrochlorothiazide/Irbesartan Tablets

Lupin Pharmaceuticals is recalling all batches of irbesartan tablets USP 75 mg, 150 mg, and 300 mg and irbesartan and hydrochlorothiazide (HCTZ) tablets USP 150 mg/12.5 mg and 300 mg/12.5 mg because ...
Nature

Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg

Approximately 43 million people in Japan suffer from hypertension. 1 The majority require a combination of antihypertensive drugs to achieve adequate blood pressure (BP) control. A cross-sectional ...
Nature

Erratum: Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials

Correction to: Hypertension Research (2014) 37, 1042–1049; doi:10.1038/hr.2014.114; published online 3 July 2014 The authors of the above paper noticed an error in ...